Education
About Us
Working with TipRanks
Follow Us
Biovaxys Technology Corp (TSE:BIOV)
:BIOV
RESEARCH TOOLSreports
BIOV Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.03 - C$0.08
Previous CloseN/A
Volume0.00
Average Volume (3M)224.29K
Market Cap
C$10.20M
Enterprise ValueC$19.98M
Total Cash (Recent Filing)C$157.41K
Total Debt (Recent Filing)C$67.72K
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Jun 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding291,525,200
10 Day Avg. Volume101,745
30 Day Avg. Volume224,286
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-26.02
Price to Sales (P/S)0.00
P/FCF Ratio-12.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
BioVaxys Technology News
PremiumCompany Announcements
BioVaxys Announces Share Consolidation and $3M Private Placement
PremiumCompany Announcements
BioVaxys and Sona Nanotech Collaborate on Innovative Cancer TherapeuticsPremiumCompany Announcements
BioVaxys and SpayVac Expand License to Target Aquaculture Market
PremiumCompany Announcements
BioVaxys Technology Corp. Revokes Cease Trade Order and Settles Debt
PremiumCompany Announcements
BioVaxys Technology Corp. Updates on Management Cease Trade Order StatusOptions Prices
Currently, No data available
---
Ownership Overview
10.05% Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
89.95% Public Companies and
Individual Investors
BIOV FAQ
What was Biovaxys Technology Corp’s price range in the past 12 months?
Biovaxys Technology Corp lowest stock price was C$0.03 and its highest was C$0.08 in the past 12 months.
What is Biovaxys Technology Corp’s market cap?
Biovaxys Technology Corp’s market cap is C$10.20M.
When is Biovaxys Technology Corp’s upcoming earnings report date?
Biovaxys Technology Corp’s upcoming earnings report date is Jun 26, 2025 which is in 7 days.
How were Biovaxys Technology Corp’s earnings last quarter?
Biovaxys Technology Corp released its earnings results on Mar 31, 2025. The company reported -C$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.004.
Is Biovaxys Technology Corp overvalued?
According to Wall Street analysts Biovaxys Technology Corp’s price is currently Overvalued.
Does Biovaxys Technology Corp pay dividends?
Biovaxys Technology Corp does not currently pay dividends.
What is Biovaxys Technology Corp’s EPS estimate?
Biovaxys Technology Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biovaxys Technology Corp have?
Biovaxys Technology Corp has 291,525,200 shares outstanding.
What happened to Biovaxys Technology Corp’s price movement after its last earnings report?
Biovaxys Technology Corp reported an EPS of -C$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 10%.
Which hedge fund is a major shareholder of Biovaxys Technology Corp?
Currently, no hedge funds are holding shares in TSE:BIOV
Company Description
Biovaxys Technology Corp
BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. It develops BVX-0320, a monovalent SARS-CoV-2 vaccine; and BVX-0918A, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, which screens for an immune system response in patients exposed to SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions; BVX-0918C for cervical cancer; BVX-0204 HPV viral vaccine; and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320; and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. The company is based in Vancouver, Canada.